With regards to uveitis, there is a large amount of new clinical trial data that need to be communicated to the retina community.

Results from several clinical studies assessing the safety and efficacy of different steroids utilizing different delivery methods for the management of DME have been recently announced

Results from 5 phase III studies on retinal vein occlusion (RVO) were recently announced. Namely, the National Institutes of Health’s SCORE (Standard Care vs Corticosteroid for RVO) study, 2 studies using dexamethazone intravitreal implant, the BRAVO (Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Branch RVO) trial, and the CRUISE (Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Central RVO) trial. This CME activity is designed to help retina specialists aggregate, interpret, and apply the new data to their clinical practice.

Results from 5 phase III studies on retinal vein occlusion (RVO) were recently announced. Namely, the National Institutes of Health’s SCORE (Standard Care vs Corticosteroid for RVO) study, 2 studies using dexamethazone intravitreal implant, the BRAVO (Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Branch RVO) trial, and the CRUISE (Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Central RVO) trial. In order for clinicians to effectively treat patients with RVO, DME, and uveitis, the educational gap between the most recent clinical research and results and then comparing and disseminating those results to clinicians must be filled. This CME activity is designed to help retina specialists aggregate, interpret, and apply the new data to their clinical practice.